Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Yuhan Corp: Expectations For Re-Rating Intact

Summary

Yuhan inked a USD785mn licensing and collaboration deal with Gilead Science this year to co-develop two drug candidates that may cure nonalcoholic steatosis hepatitis (NASH).

Last year, it also out- licensed the third-generation lung cancer drug lazertinib to Janssen.

Accordingly, we maintain BUY on Yuhan, given the additional milestone payments that it will receive over the course of the drugs’ development.

yuhan biotech

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Additional disclosure: Hyundai Motor Company is a passive shareholder in our bank.